Compare Aecom (ACM) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aecom vs Novavax Inc — how do they compare? Aecom trades at $68.17 (market cap $8.69B), while Novavax Inc trades at $9.4 (market cap $1.56B). The key difference: Aecom is far larger — about 5.6× Novavax Inc's market cap, and Aecom pays a 1.76% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ACM | NVAX | |
|---|---|---|
Market Cap | $8.69B | $1.56B |
Sector | Industrials | Health |
52-Week High | $134.35 | $11.19 |
52-Week Low | $66.86 | $6.22 |
Enterprise Value | $10.88B | $1.06B |
Dividend Yield | 1.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $67.64, down 0.15% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.53 and P/S of 0.57, while recent earnings beat expectations in Q1 2026. Analyst consensus is bullish with a $98.83 price target, though recent news includes both contract wins and legal investigations.
The outlook for ACM is mixed: strong valuation metrics and recent contract awards support upside potential, but technical weakness and legal scrutiny pose near-term risks. Earnings growth and margin expansion remain key catalysts, while investor sentiment is cautious due to the stock's 21% decline over the past three months.
Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.
Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
